Clinical trial · Observational
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Clinical Research Platform on Treatment, Quality of Life and Outcome of Patients With Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
NCT06043011CI-TRIAL-00117771RUBINrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia (CLL) | Chronic Lymphocytic Leukemia | ALIAS | 0.90 |
| Diffuse Large B-cell Lymphoma (DLBCL) | Diffuse Large B-Cell Lymphoma | ALIAS | 0.90 |
| Follicular Lymphoma (FL) | Follicular Lymphoma | ONTOLOGY_EXACT | 0.85 |
| Mantle Cell Lymphoma (MCL) | Mantle Cell Lymphoma | ONTOLOGY_EXACT | 0.85 |
| Marginal Zone Lymphoma (MZL) | Marginal Zone Lymphoma | ONTOLOGY_EXACT | 0.85 |
| Waldenström's Macroglobulinemia (WM) | Waldenstrom Macroglobulinemia | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Routine care as per site standard. | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- label
- Chronic Lymphocytic Leukemia (CLL)
- description
- Patients with CLL receiving systemic treatment (physician's choice)
- interventionNames
- Other: Routine care as per site standard.
- label
- Diffuse Large B-cell Lymphoma (DLBCL)
- description
- Patients with DLBCL receiving systemic treatment (physician's choice)
- interventionNames
- Other: Routine care as per site standard.
- label
- Follicular Lymphoma (FL)
- description
- Patients with FL receiving systemic treatment (physician's choice)
- interventionNames
- Other: Routine care as per site standard.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Confirmed diagnosis of the respective NHL * If patient is alive: signed written informed consent * For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment. * For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment. Exclusion Criteria: * No systemic therapy for respective lymphoid malignancy.
References
Publications (0)
Data not yet available
No reference posted for this study.